Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F]AlF-NOTA-A6p-FS2
- Development stage
- Unknown
- Lead developer
- Sun Yat-sen University Cancer Center
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
[18F]AlF-NOTA-A6p-FS2 is a novel fluorine-18-labeled radiopharmaceutical probe developed by the Sun Yat-sen University Cancer Center for positron emission tomography (PET) imaging of integrin α6-expressing tumors. The probe is based on a cyclic peptide (A6p) targeting the integrin α6 receptor, which is recognized as a marker for functional stem cells in multiple tumors and correlates with poor prognosis. To enhance tumor uptake and retention, the cyclic peptide was covalently modified with a fluorosulfonyl (FS) group at a specific site (FS2) and conjugated to a NOTA chelator, allowing for one-step radiolabeling with aluminum fluoride-18 ([18F]AlF). In preclinical and preliminary clinical evaluations, [18F]AlF-NOTA-A6p-FS2 demonstrated high radiochemical purity, excellent stability, and superior tumor-to-background contrast in patients with integrin α6-positive nasopharyngeal carcinoma compared to 18F-FDG.
- Other names
- 18F-AlF-NOTA-A6p-FS2AlF-NOTA-A6p-FS2AlF-NOTA-A-6p-FS2AlF-NOTA-A 6p-FS2NOTA-A6p-FS2NOTA-A-6p-FS2NOTA-A 6p-FS2
02
Targets
ITGA6 (Integrin alpha-6)
Beyond the preview
Go deeper on [18F]AlF-NOTA-A6p-FS2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [18F]AlF-NOTA-A6p-FS2.